Skip to main content

Primary sclerosing cholangitis

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Primary sclerosing cholangitis article more useful, or one of our other health articles.

Continue reading below

What is primary sclerosing cholangitis?

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder characterised by inflammation and fibrosis of intrahepatic and extrahepatic bile ducts, resulting in multifocal biliary strictures. The cause of primary sclerosing cholangitis remains unclear but hypotheses include genetic factors, lymphocyte recruitment and activation, portal bacteraemia and bile salt toxicity. Secondary sclerosing cholangitis includes conditions where infections, thrombosis, iatrogenic causes or trauma can give rise to similar clinical characteristics to PSC1 .

Epidemiology and associated diseases1 2

  • PSC is a rare disease with a prevalence of 0.2-16 per 100,000.

  • PSC commonly affects males with a median age at diagnosis of 35 years.

  • PSC accounts for 10% of all UK liver transplants.

  • There is a significant association with inflammatory bowel disease, hepatobiliary malignancies and colorectal cancer3 .

Continue reading below

Presentation4

Primary sclerosing cholangitis symptoms

  • May be asymptomatic (presenting with abnormal LFTs or hepatomegaly).

  • Jaundice and pruritus.

  • Right upper quadrant abdominal pain.

  • Fatigue, weight loss, fevers and sweats.

  • May present with complications (see 'Complications and their management', below).

Signs

  • Jaundice.

  • Hepatomegaly (may also have splenomegaly at presentation).

Later stages: signs of cirrhosis, portal hypertension or hepatic failure.

Severity

The Child-Turcotte-Pugh scale which is used to assess severity of disease includes:

  • Grade of encephalopathy.

  • Presence or absence of ascites.

  • Serum albumin level.

  • Prothrombin time.

  • Bilirubin level.

Differential diagnosis1

  • Vascular: hepatic artery thrombosis, portal hypertension biliopathy, portal cavernoma associated cholangiopathy, intra-arterial chemotherapy, sickle cell disease related cholangiopathy.

  • Trauma: trauma post-cholecystectomy, abdominal trauma.

  • Infections: AIDS-related cholangiopathy, recurrent pyogenic cholangitis.

  • Benign: intraductal stone disease.

  • Malignancy: cholangiocarcinoma.

  • Autoimmune: autoimmune sclerosing cholangitis, IgG4-related sclerosing cholangitis, systemic vasculitis.

  • Other: recurrent pancreatitis, sclerosing cholangitis in a critically ill patient, total parenteral nutrition-related cholangiopathy, histiocytosis X.

Continue reading below

Investigations4 5

Blood tests

  • Abnormal LFTs are usual. The most common abnormality is elevation of alkaline phosphatase or gamma-glutamyltransferase (GGT) level.

  • Serum transaminase levels may be normal or elevated to several times normal.

  • Bilirubin is raised in advanced PSC.

  • Serum albumin and prothrombin time (PTT) become abnormal as the disease progresses.

  • Immunoglobulin G (IgG), IgM and the serum globulin fraction levels may be raised.

  • There may also be hypergammaglobulinaemia, raised IgM levels, perinuclear antineutrophil cytoplasmic antibodies (p-ANCA), anticardiolipin (aCL) antibodies and antinuclear antibodies.

Other investigations

  • Ultrasound is the initial investigation and may show bile duct dilatation and liver and splenic changes; however, it is not diagnostic for PSC.

  • Magnetic resonance cholangiopancreatography (MRCP) is now the standard procedure to visualise the intrahepatic and extrahepatic bile ducts.

  • Endoscopic retrograde cholangiopancreatography (ERCP) or transhepatic cholangiography may also have a role but are invasive.

  • MRI may be useful to exclude other disease and evaluate the biliary system.

  • Liver biopsy is rarely diagnostic but may be useful for staging PSC.

Staging

Histological staging

There are four histological stages of primary sclerosing cholangitis:

Stage 1: degeneration of the epithelial cells lining the bile ducts, associated with inflammatory cell ductal and periportal triad infiltration and scarring.

Stage 2: fibrosis, paucity of bile ductules, periportal inflammatory cell infiltration, and piecemeal necrosis of the periportal hepatocytes.

Stage 3: severe degenerative changes, with disappearance of the bile ducts, portal-to-portal fibrous septa, and periportal cholestasis.

Stage 4: end-stage disease with secondary biliary cirrhosis.

Primary sclerosing cholangitis management6

Despite years of research, medical treatments are only at best able to help manage primary sclerosing cholangitis symptoms. Many drugs have been evaluated and found to be ineffective at halting progression of primary sclerosing cholangitis6 . Liver transplantation remains the only life-prolonging treatment for patients with end-stage disease .

Pruritus

  • Treatment options for patients with cholestatic pruritus include the anion exchange resin colestyramine, rifampicin, the opioid antagonist naltrexone and the serotonin reuptake inhibitor sertraline7 .

Nutrition

  • As with other cholestatic disorders, supplements for the fat-soluble vitamins (vitamins A, D, E, K) may be required.

  • In children, nutritional support may be needed to ensure adequate growth.

Preventing progression8

  • Systematic reviews have found no evidence of any benefit with either corticosteroids or penicillamine .

  • Ursodeoxycholic acid:

    • This gives a significant improvement in liver biochemistry and is usually well tolerated.

    • However, it has not so far been shown to give any clinical benefit and high-dose ursodeoxycholic acid (28-30 mg/kg/day) has been shown to increase the adverse events rate9 .

    • A Cochrane review concluded that there is insufficient evidence either to support or refute the use of bile acids in the treatment of PSC10 .

  • Avoid alcohol, which is a risk factor for cholangiocarcinoma development.

Surgical and endoscopic interventions

  • Strictures causing recurrent cholangitis can be treated by balloon dilatation (endoscopic or percutaneous). Stents are also used.

  • Surgical drainage procedures are possible but do not alter prognosis because of the intrahepatic component of the disease. There is a postoperative risk of cholangitis and the procedures may make later transplantation more difficult.

  • Liver transplantation is an effective treatment. The indications for liver transplantation are similar to other causes of chronic liver disease but also include intractable pruritus and recurrent cholangitis1 .

Complications and their management

Biliary complications

  • Biliary obstruction due to stones or strictures - treat with endoscopic or drainage procedures (see 'Surgical and endoscopic interventions', above).

  • Bacterial cholangitis, acute or chronic - treat with antibiotics.

Cirrhosis and associated complications

Related cancers

  • Cholangiocarcinoma and colorectal cancer are both increased in patients with PSC1 .

  • It has been recommended that:

    • Total colonoscopy with biopsies should be11 :

      • Performed in patients in whom the diagnosis of PSC has been established without known inflammatory bowel disease.

      • Repeated annually in PSC patients with colitis from the time of diagnosis of PSC.

    • Annual abdominal ultrasonography should be considered for gallbladder abnormalities.

Primary sclerosing cholangitis prognosis

  • PSC is a progressive disease of the liver characterised by inflammation and destruction of the intrahepatic and/or extrahepatic bile ducts, leading to fibrosis and ultimately liver failure, cirrhosis and an increased risk of malignancy12 .

  • PSC can be classified into small-duct or large-duct types, which seems to affect prognosis13 :

    • Small-duct PSC has a better prognosis, with longer transplant-free survival.

    • Also, it appears that cholangiocarcinoma is unlikely with small-duct PSC.

  • Prognosis after liver transplant:

    • Survival post-transplant is about 94% 1 year, 86% at 5 years and 70% at 10 years1 .

    • However, liver transplantation does not guarantee a cure, with 20% recurrence in the graft2 .

Primary biliary cholangitis and primary sclerosing cholangitis

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are similarly named, so there is potential for confusion.

  • Both involve primary sclerosis of bile ducts:

    • PBC affects small interlobular bile ducts; PSC affects intrahepatic and extrahepatic bile ducts.

  • PBC occurs predominantly in women, and PSC predominantly in men.

  • PBC is an autoimmune condition linked to the presence of antimitochondrial antibodies.

  • The cause of PSC is unclear, although the process is inflammatory and there is an association with inflammatory bowel disease.

  • Mayo clinic scoring systems are used to assess prognosis; the two scoring systems differ.

  • Liver transplantation can be curative for PBC and PSC. Each has a significant recurrence rate.

Further reading and references

  • PSC Support
  1. Nayagam JS, Pereira SP, Devlin J, et al; Controversies in the management of primary sclerosing cholangitis. World J Hepatol. 2016 Feb 18;8(5):265-72. doi: 10.4254/wjh.v8.i5.265.
  2. Goode EC, Rushbrook SM; A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis. 2016 Jan;7(1):68-85. doi: 10.1177/2040622315605821.
  3. Rizvi S, Eaton JE, Gores GJ; Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2152-65. doi: 10.1016/j.cgh.2015.05.035. Epub 2015 Jun 5.
  4. Lutz H, Trautwein C, Tischendorf JW; Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int. 2013 Dec 23;110(51-52):867-74. doi: 10.3238/arztebl.2013.0867.
  5. Williamson KD, Chapman RW; Primary sclerosing cholangitis. Dig Dis. 2014;32(4):438-45. doi: 10.1159/000358150. Epub 2014 Jun 23.
  6. Rawla P, Samant H; Primary Sclerosing Cholangitis
  7. Kremer AE, Bolier R, van Dijk R, et al; Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis. 2014;32(5):637-45. doi: 10.1159/000360518. Epub 2014 Jul 14.
  8. Saffioti F, Gurusamy KS, Hawkins N, et al; Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017 Mar 28;3:CD011343. doi: 10.1002/14651858.CD011343.pub2.
  9. Sinakos E, Lindor K; Treatment options for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):473-88.
  10. Poropat G, Giljaca V, Stimac D, et al; Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD003626. doi: 10.1002/14651858.CD003626.pub2.
  11. Appanna G, Kallis Y; An update on the management of cholestatic liver diseases. Clin Med (Lond). 2020 Sep;20(5):513-516. doi: 10.7861/clinmed.2020-0697.
  12. Ali AH, Carey EJ, Lindor KD; Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb;4(1):1-6. doi: 10.5582/irdr.2014.01018.
  13. Bjornsson E, Olsson R, Bergquist A, et al; The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008 Apr;134(4):975-80. Epub 2008 Jan 17.

Article history

The information on this page is written and peer reviewed by qualified clinicians.

symptom checker

Feeling unwell?

Assess your symptoms online for free